If there's a buyout, it will be based on the market cap at the time. Double the current market cap is roughly the best most companies can do. I don't believe that their is any figure that can be named that isn't achievable in time if the DCVAX-L and Direct prove effective in most solid cancers. Clearly it will take a lot of time, and if the company accepts an offer before that happens, it will be for less.
When we talk about $20 to $40 billion it is very possible to achieve on the strength of DCVAX-L in brain cancer alone, if it is being used in much of the world. I see that possible in a couple years. Perhaps less if major media highlights what the company is doing.
We've all seen other products claiming advancements in GBM, they are true, but nothing close to what DCVAX-L does when combined with other products. It won't be that long before much of the world knows that this is the case. How much you want for NWBO may purely be a case of how long you're willing to wait.
Gary
News 
Market Data 
Discover 
